These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 9247310)
1. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oh JW; Katz A; Harroch S; Eisenbach L; Revel M; Chebath J Oncogene; 1997 Jul; 15(5):569-77. PubMed ID: 9247310 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Flørenes VA; Lu C; Bhattacharya N; Rak J; Sheehan C; Slingerland JM; Kerbel RS Oncogene; 1999 Jan; 18(4):1023-32. PubMed ID: 10023678 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-9 (IL-9) induces cell growth arrest associated with sustained signal transducer and activator of transcription activation in lymphoma cells overexpressing the IL-9 receptor. Demoulin JB; Van Snick J; Renauld JC Cell Growth Differ; 2001 Mar; 12(3):169-74. PubMed ID: 11306517 [TBL] [Abstract][Full Text] [Related]
6. Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells. Kang KW; Wagley Y; Kim HW; Pokharel YR; Chung YY; Chang IY; Kim JJ; Moon JS; Kim YK; Nah SY; Kang HS; Oh JW Free Radic Biol Med; 2007 Jan; 42(2):215-27. PubMed ID: 17189827 [TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin 6 and leukemia inhibitory factor: role in growth inhibition. Abdollahi A; Lord KA; Hoffman-Liebermann B; Liebermann DA Cell Growth Differ; 1991 Aug; 2(8):401-7. PubMed ID: 1793735 [TBL] [Abstract][Full Text] [Related]
8. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032 [TBL] [Abstract][Full Text] [Related]
9. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Oh JW; Revel M; Chebath J Cytokine; 1996 May; 8(5):401-9. PubMed ID: 8726669 [TBL] [Abstract][Full Text] [Related]
10. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis. Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948 [TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes. Gabay C; Silacci P; Genin B; Mentha G; Le Coultre C; Guerne PA Eur J Immunol; 1995 Aug; 25(8):2378-83. PubMed ID: 7545121 [TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin 6 receptor is biologically active in vivo. Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033 [TBL] [Abstract][Full Text] [Related]
13. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Nguyen H; Lin R; Hiscott J Oncogene; 1997 Sep; 15(12):1425-35. PubMed ID: 9333018 [TBL] [Abstract][Full Text] [Related]
14. Directly linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3. Takizawa T; Yanagisawa M; Ochiai W; Yasukawa K; Ishiguro T; Nakashima K; Taga T Cytokine; 2001 Mar; 13(5):272-9. PubMed ID: 11243705 [TBL] [Abstract][Full Text] [Related]
15. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. Peters M; Odenthal M; Schirmacher P; Blessing M; Fattori E; Ciliberto G; Meyer zum Buschenfelde KH; Rose-John S J Immunol; 1997 Aug; 159(3):1474-81. PubMed ID: 9233646 [TBL] [Abstract][Full Text] [Related]
16. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Silvani A; Ferrari G; Paonessa G; Toniatti C; Parmiani G; Colombo MP Cancer Res; 1995 May; 55(10):2200-5. PubMed ID: 7743524 [TBL] [Abstract][Full Text] [Related]
18. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436 [TBL] [Abstract][Full Text] [Related]
19. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors. Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033 [TBL] [Abstract][Full Text] [Related]
20. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation. Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]